<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220314054282N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-19</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>comprehensive empowerment program in older patients with diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of comprehensive empowerment program on age-related outcomes in older patients with diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67245</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Subjects will be randomly assigned to the intervention and control groups by blocking; selecting subjects will be from person to person. For allocation concealment, each control and intervention group will be given a letter (A and B), and blocks will be put into the non-transparent envelopes after production;  then, the first subject will be asked to pick an envelope; the first letter will demonstrate the group of the mentioned subject and the other letters in this block will show the order of following subjects. After finishing this block, the next subject will be asked to pick an envelope, and the assignment will be implemented in this manner till the sampling is completed, Blinding description: the information given to the analyser will be in codes which compliment the classification to the intervention and control groups and the subjects themselves.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Being diagnosed of diabetes type 2 for at least one year. Condition 2: Being 65 years old and more. Condition 3: Mark 5 or more in constipation assessment scale.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: will comprehensive empowerment program besides routine care. The comprehensive empowerment program will be implemented in the physical aspect (introduction to the disease, monitoring the signs and symptoms, constipation management, and the importance of therapeutic adherence), psycho-social aspect (stress management and relaxation methods), and spiritual aspect (promotion of hope and focusing on the strengths and recommendation of coping strategies and personal meaning of the subject in life). The empowerment sessions will be in-person, 30 to 60 minutes (as needed), in groups of a few. They will be held in an environment with suitable ventilation and considering health protocols. The number of sessions and the context will be determined, edited, and validated under the suggestion of consultants who are specialists in the mentioned aspects and empowerment. Participants will be followed up by means of a phone call between sessions to be answered if there is any question or ambiguity. The presence of a key family caregiver will be necessary for some sessions so the family caregiver will be asked if there is any question or ambiguity. Intervention 2: Control group: will receive routine care.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzieh Pazokian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Niyayesh Complex, Niyayesh Cross-Section, ValiAsr St, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8865 5372</telephone>
        <email>Pazokian@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Pazokian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Niyayesh Complex, Niyayesh Cross-Section, ValiAsr St, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8865 5372</telephone>
        <email>pazokian@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being diagnosed of diabetes for at least one year.
Being able to speak Farsi.
Being 65 years old and more
Mark 5 or more in constipation assessment scale
The older adult or his/her key caregiver has access and ability to use electronic devices for connecting to the web, watching video and reading text.</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Affliction of covid-19 during the in-person sessions, mental health or cognitive disorders
Participation in similar empowerment programs
Being in the acute and emergency conditions like keto-acidosis, and life-threatening hyperglycemic attacks
Not being able to continue the participation (death, intensive care needs, immigrations)
Not participating in all sessions or even alternative/compensatory sessions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
      <hc_code></hc_code>
      <hc_code>K59.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Constipation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: will comprehensive empowerment program besides routine care. The comprehensive empowerment program will be implemented in the physical aspect (introduction to the disease, monitoring the signs and symptoms, constipation management, and the importance of therapeutic adherence), psycho-social aspect (stress management and relaxation methods), and spiritual aspect (promotion of hope and focusing on the strengths and recommendation of coping strategies and personal meaning of the subject in life). The empowerment sessions will be in-person, 30 to 60 minutes (as needed), in groups of a few. They will be held in an environment with suitable ventilation and considering health protocols. The number of sessions and the context will be determined, edited, and validated under the suggestion of consultants who are specialists in the mentioned aspects and empowerment. Participants will be followed up by means of a phone call between sessions to be answered if there is any question or ambiguity. The presence of a key family caregiver will be necessary for some sessions so the family caregiver will be asked if there is any question or ambiguity.</i_keyword>
      <i_keyword>Control group: will receive routine care.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Glycemic control. Timepoint: At first and then 3 months later. Method of measurement: Will be determined by draining 2-3 cc blood and measuring glycosylated hemoglobin at first and then 3 months later.</prim_outcome>
      <prim_outcome>Constipation. Timepoint: Measuring at the beginning, one month after starting the study and 3 months after starting the study. Method of measurement: Utilizing constipation assessment scale.</prim_outcome>
      <prim_outcome>Polypharmacy. Timepoint: Measuring at the beginning, one month after starting the study and 3 months after starting the study. Method of measurement: Utilizing Screening Tool of Older persons' potentially inappropriate prescriptions  (STOPP) Version 2.</prim_outcome>
      <prim_outcome>Active aging. Timepoint: Measuring at the beginning, one month after starting the study and 3 months after starting the study. Method of measurement: Active Aging Measurement Instrument.</prim_outcome>
      <prim_outcome>Health costs. Timepoint: Measuring at the beginning, one month after starting the study and 3 months after starting the study. Method of measurement: Researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: Measuring at the beginning, one month after starting the study and 3 months after starting the study. Method of measurement: Using manual blood pressure measurement instrument under TRUE consortium standards.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-25</approval_date>
        <contact_name>Research Ethics Committee of School of Pharmacy and Nursing &amp; Midwifery- Shahid Beheshti University</contact_name>
        <contact_address>Vali Asr Ave., Niayesh Cross Road, Niayesh Complex, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
